screening for egfr mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program a hellenic cooperative oncology group study表皮生长因子受体突变筛查患者的头部和颈部癌症治疗与吉非替尼同情使用程序希腊合作肿瘤组织的一项研究.pdf

Hindawi Publishing Corporation Journal of Oncology Volume 2010, Article ID 709678, 10 pages doi:10.1155/2010/709678 Research Article Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study Samuel Murray,1, 2 Mattheos Bobos,3 Nikolaos Angouridakis,4 Angelos Nikolaou,4 Helena Linardou,5 Evangelia Razis,6 and George Fountzilas7 1 GeneKOR S.A. Glyka Nera, 15354, Athens, Greece 2 BioMarker Solutions, 23 Barnsbury Square, London N1 1JP, UK 3 Laboratory of Molecular Oncology, Hellenic Foundation of Cancer Research, School of Medicine, Aristotle University of Thessaloniki, 54006, Thessaloniki, Greece 4 ENT Department, “AHEPA” Hospital, School of Medicine, Aristotle University of Thessaloniki, 54006, Thessaloniki, Greece 5 1st Department of Oncology, “Metropolitan” Hospital, N. Faliro, 18547, Athens, Greece 6 2nd Department of Oncology, “Hygeia” Hospital, 15123, Athens, Greece 7 Department of Medical Oncology, “Papageorgiou” Hospital, School of Medicine, Aristotle University of Thessaloniki, 54006, Thessaloniki, Greece Correspondence should be addressed to Samuel Murray, smbhsam@ Received 24 July 2010; Revised 19 October 2010; Accepted 31 October 2010 Academic Editor: M. Roach Copyright © 2010 Samuel Murray et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background and Aim. EGFR is commonly expressed in cancers of the head and neck (H and N), and anti-EGFR agents have demonstrated improvements in outcomes (TTP and OS). The aim of this study was to de